RA
BTAI icon

Rational Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Rational Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-426
Closed -$48K – 540
2019
Q3 		$48K Buy
+426
New +$67.2K 0.02% 367

Other funds holding BTAI

AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rational Advisors's BTAI Position: Q4 2019 in Review

Rational Advisors sold out of BioXcel Therapeutics (BTAI) in Q4 2019, closing a stake of 426 shares — an estimated $48K sold.

Rational Advisors first reported a position in BTAI in Q3 2019 and held it in 1 quarter. The position peaked at $48K in Q3 2019. 43 funds tracked by Wall St. Rank hold BTAI as of Q4 2019.

  • Rational Advisors reported no remaining BioXcel Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Rational Advisors sold 426 BioXcel Therapeutics shares in Q4 2019, an estimated $48K.
  • Rational Advisors first reported a position in BioXcel Therapeutics in Q3 2019 and held it in 1 quarter.
  • Rational Advisors's BioXcel Therapeutics position peaked at $48K in Q3 2019.
  • 43 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2019.

Based on Rational Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.